23 C
New York
Thursday, June 11, 2026

Tag: loss

newssourceFORcompanyinformationcontent1marketreleases

Active Optical Cable Market Fueled by AI Data-Center Traffic, Says Strategic Market Research

Global Active Optical Cable Market to grow from USD 3.6 billion in 2024 to USD 7.8 billion by 2030 as data centers, telecom operators,...

Active Optical Cable Market Fueled by AI Data-Center Traffic, Says Strategic Market Research

Global Active Optical Cable Market to grow from USD 3.6 billion in 2024 to USD 7.8 billion by 2030 as data centers, telecom operators,...

Thian Ong Financial Academy Shares AI Development Insights at Science x AI Summit 2026

KUALA LUMPUR, Malaysia, June 08, 2026 (GLOBE NEWSWIRE) -- At the Science x AI Summit 2026 held in Silicon Valley on May 12, the latest technological advances in the global AI research and industrial communities became the focus of attention. Experts from Thian Ong Financial Academy joined the discussions as the scaling limits of large models, AI Agents, autonomous reasoning systems, and the development path of research-grade AI triggered extensive discussions among participating experts.

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

GoveeLife Launches Smart Countertop Ice Maker 2 Pro for Iced Coffee and Summer Hosting

The bullet ice maker delivers first ice in as fast as 3 minutes, up to 47 lb of daily ice production, and up to...

Tethis to launch SmartBioSurface® slides at EACR Conference

MILAN, June 8, 2026 /PRNewswire/ -- Tethis S.p.A., a pioneering life sciences and diagnostics company, today announces the commercial launch of SmartBioSurface slides, an...

ROHM’s SiC MOSFET Adopted in BBU for AI Servers as HVDC Architectures Advance

KYOTO, Japan, June 8, 2026 /PRNewswire/ -- ROHM Co., Ltd. has announced that its 750V SiC MOSFET has been adopted in a BBU (Battery Backup...

New Linux Foundation Report Finds AI is Driving Positive Tech Hiring Trends in Europe Amid Growing Security and Skills Gaps

Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...

Toobit Adds XLM to Fixed Earn Series with Limited-Time 60% APR

GEORGE TOWN, Cayman Islands, June 08, 2026 (GLOBE NEWSWIRE) -- Toobit, the award-winning global cryptocurrency exchange, today announces the addition of Stellar (XLM) to its high-yield Fixed Earn series, offering traders an opportunity to capture 60% APR on their staked assets.

HTX Launches “Appreciation Program” with Over $10 Million to Reward User Trust

APIA, Samoa, June 8, 2026 /PRNewswire/ -- Amid the rapid iteration of the crypto industry and the constant shifts in market conditions, the relationship...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

- A word from our sponsors -

spot_img
HomeTagsLoss

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers